NAMS

Business Context and Reporting Period

NewAmsterdam Pharma Company N.V. (NAMS) is a late-stage biopharmaceutical company focused on developing obicetrapib, an oral CETP inhibitor for lowering LDL-C in patients with cardiometabolic diseases. The filing covers the fiscal year ended December 31, 2024. The company has no approved products and generates revenue solely from a licensing agreement with Menarini International Licensing S.A. for European commercialization rights.

Key Financial Metrics

Note: The company reported no product revenue. Revenue growth was driven by milestone recognition and R&D cost reimbursements under the Menarini License.

Material Changes vs. Prior Period

• Revenue Increase: Revenue increased 223% to $45.6 million, primarily due to $27.3 million recognized for a clinical success milestone and $11.9 million in development cost reimbursements from Menarini.
• Net Loss Expansion: Net loss widened by $64.7 million to $241.6 million. This was driven by a $37.0 million fair value loss on earnout liabilities (probability of achievement increased to 100%) and a $38.6 million fair value loss on warrants, partially offset by higher interest income ($16.9 million).
• Expense Shifts: Research and Development (R&D) expenses decreased slightly by $8.0 million to $151.4 million due to lower manufacturing costs. Conversely, Selling, General, and Administrative (SG&A) expenses surged 87% to $70.4 million, driven by personnel costs and commercial preparation.
• Liquidity Boost: Cash balances more than doubled to $771.7 million following two follow-on equity offerings in February and December 2024, which generated net proceeds of approximately $645 million combined.

Guidance, Outlook, and Risks

• Clinical Progress: The company announced positive topline data for three pivotal Phase 3 trials in 2024: BROADWAY (monotherapy), BROOKLYN (monotherapy), and TANDEM (fixed-dose combination with ezetimibe). All met primary endpoints with significant LDL-C reductions.
• Outlook: Management expects to submit a New Drug Application (NDA) for obicetrapib monotherapy and the fixed-dose combination shortly after the completion of the PREVAIL cardiovascular outcomes trial (CVOT), which is expected to conclude by the end of 2026.
• Capital Requirements: While current cash reserves are sufficient for operations, the company anticipates continuing to incur significant losses until product approval and commercialization. Future funding may be required via equity, debt, or collaborations.
• Key Risks:
  • Regulatory Approval: No guarantee that obicetrapib will receive FDA or EMA approval despite positive trial data.
  • Commercialization: Reliance on Menarini for European commercialization and the need to build a U.S. commercial infrastructure.
  • Competition: Intense competition from PCSK9 inhibitors and other emerging oral therapies.
  • Internal Controls: The company previously identified material weaknesses in internal controls over financial reporting, which management states have been remediated as of December 31, 2024.

Investor Verification Checklist

• Cash Runway: Verify the projected burn rate against the $771.7 million cash balance to confirm sufficiency through the PREVAIL CVOT completion (end of 2026).
• Menarini Milestones: Confirm the specific terms and remaining potential value of the €863 million in potential milestone payments under the Menarini License.
• Derivative Liabilities: Monitor the fair value of the earnout liability ($44.8 million) and warrant liability ($37.5 million), as fluctuations in share price will directly impact net income.
• Internal Controls: Review the auditor's attestation report to confirm the effectiveness of the remediated internal controls over financial reporting.
• Patent Expiry: Assess the timeline of the patent portfolio, noting that first-generation patents expire between 2025 and 2027, while second and third-generation patents extend into the 2030s and 2040s.